279 related articles for article (PubMed ID: 31880795)
21. The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial.
Moore CM; Robertson NL; Jichi F; Damola A; Ambler G; Giganti F; Ridout AJ; Bott SR; Winkler M; Ahmed HU; Arya M; Mitra AV; McCartan N; Freeman A; Jameson C; Castro R; Gambarota G; Whitcher BJ; Allen C; Kirkham A; Emberton M
J Urol; 2017 Apr; 197(4):1006-1013. PubMed ID: 27871928
[TBL] [Abstract][Full Text] [Related]
22. Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.
Xu J; Resurreccion WK; Shi Z; Wei J; Wang CH; Zheng SL; Hulick PJ; Ross AE; Pavlovich CP; Helfand BT; Isaacs WB
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):422-430. PubMed ID: 35347252
[TBL] [Abstract][Full Text] [Related]
23. Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
Xu J; Isaacs WB; Mamawala M; Shi Z; Landis P; Petkewicz J; Wei J; Wang CH; Resurreccion WK; Na R; Bhanji Y; Novakovic K; Walsh PC; Zheng SL; Helfand BT; Pavlovich CP
Prostate; 2021 Jul; 81(10):703-709. PubMed ID: 33956350
[TBL] [Abstract][Full Text] [Related]
24. Family history is significantly associated with prostate cancer and its early onset in Chinese population.
Xu Y; Huang D; Wu Y; Ye D; Zhang N; Gao Y; Xu D; Na R; Xu J
Prostate; 2019 Nov; 79(15):1762-1766. PubMed ID: 31497879
[TBL] [Abstract][Full Text] [Related]
25. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.
Na R; Ye D; Qi J; Liu F; Lin X; Helfand BT; Brendler CB; Conran C; Gong J; Wu Y; Gao X; Chen Y; Zheng SL; Mo Z; Ding Q; Sun Y; Xu J
Asian J Androl; 2016; 18(4):525-9. PubMed ID: 27140652
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study.
Akaza H; Kanetake H; Tsukamoto T; Miyanaga N; Sakai H; Masumori N; Nakatsu H; Sagiyama K; Sakamoto S; Endo Y; Yamanouchi T;
Jpn J Clin Oncol; 2011 Mar; 41(3):417-23. PubMed ID: 21123311
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial.
Kattan MW; Earnshaw SR; McDade CL; Black LK; Andriole GL
Appl Health Econ Health Policy; 2011 Sep; 9(5):305-15. PubMed ID: 21875161
[TBL] [Abstract][Full Text] [Related]
28. Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.
Andriole GL; Bostwick DG; Gomella LG; Marberger M; Montorsi F; Tammela TL; Tindall DJ; Fowler IL; Garges HP; Wilson TH; Castro R
Urology; 2014 Aug; 84(2):393-9. PubMed ID: 24916669
[TBL] [Abstract][Full Text] [Related]
29. Concept and benchmarks for assessing narrow-sense validity of genetic risk score values.
Yu H; Shi Z; Wu Y; Wang CH; Lin X; Perschon C; Isaacs WB; Helfand BT; Lilly Zheng S; Duggan D; Mo Z; Lu D; Xu J
Prostate; 2019 Jul; 79(10):1099-1105. PubMed ID: 31037745
[TBL] [Abstract][Full Text] [Related]
30. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
[TBL] [Abstract][Full Text] [Related]
31. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
32. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
33. Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population.
Oh JJ; Lee SJ; Hwang JY; Kim D; Lee SE; Hong SK; Ho JN; Yoon S; Sung J; Kim WJ; Byun SS
Oncotarget; 2017 Jul; 8(27):43934-43943. PubMed ID: 28380453
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
35. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
36. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
[TBL] [Abstract][Full Text] [Related]
37. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
[TBL] [Abstract][Full Text] [Related]
38. [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN PATIENTS RECEIVING DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA].
Endo T; Kamiya N; Yano M; Oka R; Lee FC; Utsumi T; Kamijima S; Nishimi D; Takanami M; Hiruta N; Suzuki H
Nihon Hinyokika Gakkai Zasshi; 2015 Jul; 106(3):156-62. PubMed ID: 26419072
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation.
Sciarra A; Maggi M; Fasulo A; Salciccia S; Gentile V; Cattarino S; Gentilucci A
Urologia; 2017 Aug; 84(3):158-164. PubMed ID: 28430341
[TBL] [Abstract][Full Text] [Related]
40. Head-to-Head Comparison of Family History of Colorectal Cancer and a Genetic Risk Score for Colorectal Cancer Risk Stratification.
Weigl K; Hsu L; Knebel P; Hoffmeister M; Timofeeva M; Farrington S; Dunlop M; Brenner H
Clin Transl Gastroenterol; 2019 Dec; 10(12):e00106. PubMed ID: 31800541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
